Physician profile

Vasu Pandrangi

Plastic Surgery · Cleveland, OH

NPI 1275648792

$803.79

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$161.22

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Integra Lifesciences Corporation $324.18 2019-2022
Smith+Nephew, INC. $169.52 2019
Kerecis Limited $143.33 2024 Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose
Elutia, INC. $97.89 2019
Procept Biorobotics Corporation $17.89 2023 Aquabeam Robotic System
Baxter Healthcare $17.47 2020
Bayer Healthcare Pharmaceuticals INC. $13.80 2022
Allergan, INC. $13.54 2019
Aroa Biosurgery Incorporated $6.17 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Vasu Pandrangi

$803.79

in general payments reported 2019-2025

Years
2019-2024
Top company
Integra Lifesciences Corporation

https://glasscript.com/doctor/12206/vasu-pandrangi

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.